相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Translational Status of Cancer Liquid Biopsies
Sinisa Bratulic et al.
REGENERATIVE ENGINEERING AND TRANSLATIONAL MEDICINE (2021)
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
ENDOCRINE-RELATED CANCER (2019)
Liquid biopsy in breast cancer: A comprehensive review
Sahar Alimirzaie et al.
CLINICAL GENETICS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis
Navid Sobhani et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
Dimitrios Zardavas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA
Michael J Duffy et al.
TUMOR BIOLOGY (2018)
The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment
Hanjiao Qin et al.
PEERJ (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
A systematic literature review of the clinical prognosis of HR+/HER2-advanced or metastatic breast cancer with and without PIK3CA mutation.
Elizabeth J. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
Genomic mutation-driven metastatic breast cancer therapy: a single center experience
Yuan Yuan et al.
ONCOTARGET (2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Zachary S. Zumsteg et al.
CLINICAL CANCER RESEARCH (2016)
Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice
Michael F. Press et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer
Hyo Sook Han et al.
CLINICAL BREAST CANCER (2016)
Comparative genomic analysis of primary tumors and metastases in breast cancer
Francois Bertucci et al.
ONCOTARGET (2016)
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Howard M. Stern et al.
CLINICAL CANCER RESEARCH (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
The search for ESR1 mutations in breast cancer
Steffi Oesterreich et al.
NATURE GENETICS (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer
Suzanne A. Eccles et al.
BREAST CANCER RESEARCH (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma
Sophia Apple et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
Todd W. Miller et al.
BREAST CANCER RESEARCH (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Effect of fixatives and tissue processing on the content and integrity of nucleic acids
M Srinivasan et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
分享论文
